News › Clinical Practice, Industry News, Patient Care

Laseroptek Co. Ltd. Announces U.S. Launch of Pallas Solid-state UVB Medical Dermatology Laser

August 12, 2020

Laseroptek Co. Ltd., a developer and manufacturer of laser devices for aesthetic and medical dermatology, has announced the launch of its Pallas solid-state 311-nm UVB laser in the United States. The Pallas laser is FDA-cleared for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma.
Pallas is the fifth Laseroptek laser device to receive FDA clearance in the U.S. for dermatological treatments and brings to the U.S. market the world’s first solid-state UVB laser delivering efficacious and safe treatment for a variety of skin conditions that collectively affect close to a billion people worldwide.
Read more at PR Newswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Merz Aesthetics’ Radiesse Receives FDA Approval for Décolleté Wrinkles
    • New Book “Get Found, Get Booked” Reveals a Smarter, Ethical Approach to Marketing for Med Spas and Wellness Practices
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available